Is it safe to refill Titradose (isosorbide dinitrate) for a patient with chronic kidney disease?

Is Titradose (Isosorbide Dinitrate) Safe to Refill in Chronic Kidney Disease?

Yes, Titradose (isosorbide dinitrate) is safe to refill for patients with chronic kidney disease, as the drug does not require dose adjustment in CKD and has demonstrated favorable outcomes in dialysis-dependent patients.

Pharmacokinetic Safety in CKD

Isosorbide dinitrate has favorable pharmacokinetics in renal failure that support its safe use:

• No significant accumulation occurs in CKD patients 1. Studies show no striking difference in plasma concentrations between patients with and without renal failure after oral administration, except for slightly higher isosorbide 5-mononitrate levels in uremic patients 1.

• Minimal dialysis removal 2. In hemodialysis patients, only 0.5% of the administered dose (0.3 mg during 5-hour dialysis) is removed, with no clinically significant impact on plasma levels 2.

• Chronic renal failure does not alter drug handling 3. Multiple studies confirm that renal failure does not influence plasma concentrations of isosorbide dinitrate or its metabolites 3, 4.

Clinical Evidence Supporting Use in CKD

The most compelling evidence comes from recent real-world data:

• Reduced mortality in dialysis patients 5. A large USRDS retrospective study of 6,306 dialysis patients with heart failure showed hydralazine-isosorbide dinitrate (H-ISDN) was associated with significantly lower all-cause mortality (HR 0.48,95% CI 0.43-0.54), cardiovascular death (HR 0.62), and sudden cardiac death (HR 0.62) 5.

• Well-tolerated in maintenance hemodialysis 6. A randomized controlled pilot trial demonstrated that all participants completed dose escalation to the target dose (40 mg three times daily), with only 2 requiring dose reductions. Importantly, recurrent intradialytic hypotension was actually less frequent with H-ISDN compared to placebo 6.

Guideline Support for Use

While the 2022 AHA/ACC/HFSA Heart Failure Guidelines 7 recommend hydralazine-isosorbide dinitrate primarily for African Americans with HFrEF (Class 1 recommendation), they also note:

• Consider use in patients intolerant of first-line agents due to renal insufficiency 7
• The combination may be a therapeutic option when ACE inhibitors or ARBs cannot be used 7

The KDIGO 2024 CKD Guidelines 8 do not contraindicate nitrates in CKD and focus on other medication classes (RASi, SGLT2i, MRA).

Key Safety Considerations

Monitor for these specific issues:

Hypotension risk 9:

• Check blood pressure before refilling, especially in volume-depleted patients
• The FDA label warns about severe hypotension, particularly with concomitant phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil) or riociguat 9
• However, clinical trial data shows intradialytic hypotension may actually decrease 6

Common side effects in CKD patients 6:

• Headache (most common)
• Nausea (significantly more frequent: 1.90 vs 0.50 events/patient-year)
• Gastrointestinal symptoms

No dose adjustment needed 1, 3, 4:

• Standard dosing applies regardless of GFR
• No need to reduce dose based on renal function alone

Practical Refill Algorithm

1. Verify no contraindications 9:

   • Not taking PDE5 inhibitors or riociguat
   • No known allergy to isosorbide dinitrate

2. Assess tolerance:

   • Review for symptomatic hypotension
   • Check for intolerable headaches or GI symptoms

3. Blood pressure check:

   • Ensure patient is not severely hypotensive
   • If borderline low BP, consider timing relative to dialysis sessions

4. Refill is appropriate if:

   • Patient tolerating current dose
   • Blood pressure adequate
   • No new contraindications

Important Caveats

• Acute settings: The FDA label 9 notes that benefits in acute MI or acute CHF are not established, and careful hemodynamic monitoring is needed in these situations
• Methemoglobinemia: Theoretical risk with overdose 9, but clinically insignificant at therapeutic doses
• Heart failure admissions: The USRDS study 5 showed increased HF hospitalizations with H-ISDN use (195.5 vs 73.4 events/100-PY), though this likely reflects confounding by indication (sicker patients receiving the drug)

Bottom line: Refill Titradose safely in CKD patients who are tolerating the medication, with standard monitoring for hypotension and side effects. No dose adjustment is required based on renal function alone.